Joshua K. Tobias

Vienna, 1090, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications

Entamoeba histolytica - binding of the lipopeptidophosphoglycan - specific monoclonal antibody EH5 to dextrans.

Entamoeba histolytica - binding of the lipopeptidophosphoglycan - specific monoclonal antibody EH5 to dextrans.

Journal: Carbohydrate research
Published: May 28, 2025

The benefits of Lactiplantibacillus plantarum: From immunomodulator to vaccine vector.

The benefits of Lactiplantibacillus plantarum: From immunomodulator to vaccine vector.

Journal: Immunology letters
Published: November 01, 2024

SARS-CoV-2 Vaccines: The Advantage of Mucosal Vaccine Delivery and Local Immunity.

SARS-CoV-2 Vaccines: The Advantage of Mucosal Vaccine Delivery and Local Immunity.

Journal: Vaccines
Published: June 12, 2024

Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON).

Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON).

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 14, 2024

Preclinical and Clinical Observations Implying Combination Therapy to Enhance the Efficacy of the Her-2/neu B-Cell Peptide-Based Vaccine HER-Vaxx and to Prevent Immune Evasion.

Preclinical and Clinical Observations Implying Combination Therapy to Enhance the Efficacy of the Her-2/neu B-Cell Peptide-Based Vaccine HER-Vaxx and to Prevent Immune Evasion.

Journal: International journal of molecular sciences
Published: November 20, 2023

A Biomimetic, Silaffin R5-Based Antigen Delivery Platform.

A Biomimetic, Silaffin R5-Based Antigen Delivery Platform.

Journal: Pharmaceutics
Published: November 28, 2022

Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer.

Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer.

Journal: Cancers
Published: October 12, 2022

Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers.

Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers.

Journal: Frontiers in oncology
Published: July 22, 2022

Radiation Therapy and Indigenous Peoples in Canada and Australia: Building Paths Toward Reconciliation in Cancer Care Delivery.

Radiation Therapy and Indigenous Peoples in Canada and Australia: Building Paths Toward Reconciliation in Cancer Care Delivery.

Journal: International journal of radiation oncology, biology, physics
Published: May 17, 2022

Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model.

Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model.

Journal: Translational oncology
Published: February 14, 2022

NKG2A-checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA-E.

NKG2A-checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA-E.

Journal: Immunology
Published: February 08, 2022

Vaccination against Her-2/neu, with focus on peptide-based vaccines.

Vaccination against Her-2/neu, with focus on peptide-based vaccines.

Journal: ESMO open
Published: November 03, 2021
Showing 1-12 of 43

Last Updated: 09/26/2026